Cerebral microbleeds and stroke: more questions than answers

Ranawaka, U.K.

dc.contributor.author	Ranawaka, U.K.
dc.date.accessioned	2022-07-21T05:34:19Z
dc.date.available	2022-07-21T05:34:19Z
dc.date.issued	2021
dc.identifier.citation	Sri Lanka Journal of Neurology.2021;8(1):10–14.	en_US
dc.identifier.issn	2279-2295
dc.identifier.uri	http://repository.kln.ac.lk/handle/123456789/24938
dc.description.abstract	With the widespread availability of MRI scanning, cerebral microbleeds (CMBs) are being increasingly recognized in patients with stroke and in healthy individuals. As CMBs are commonly viewed as markers of increased risk of intracerebral haemorrhage (ICH), there are concerns regarding the use of antithrombotic agents (antiplatelets, and especially anticoagulants) in the presence of CMBs, even in patients at high risk of ischaemic events. The use of antiplatelet or anticoagulant therapy in the presence of CMBs, balancing the risk of possible intracranial bleeding, is one of the most contentious contemporary issues in stroke medicine.	en_US
dc.language.iso	en	en_US
dc.publisher	Association of Sri Lankan Neurologists	en_US
dc.subject	Cerebral microbleeds	en_US
dc.subject	Stroke	en_US
dc.subject	Intracerebral haemorrhage	en_US
dc.title	Cerebral microbleeds and stroke: more questions than answers	en_US
dc.type	Article	en_US